← Search & browse all drugs
ANTIINFECTIVES FOR SYSTEMIC USE › ANTIVIRALS FOR SYSTEMIC USE › DIRECT ACTING ANTIVIRALS › Neuraminidase inhibitors
peramivir
J05AH03
Forms & Strengths
- Intravenous solution: 200 mg/20 mL (10 mg/mL) in single-dose vials
Adult Dosing
- Acute uncomplicated influenza: 600 mg administered as a single intravenous infusion over 15 to 30 minutes, initiated within 2 days of symptom onset
Pediatric Dosing
- Pediatric patients 6 months and older with acute uncomplicated influenza: 12 mg/kg (up to a maximum single dose of 600 mg) administered as a single intravenous infusion over 15 to 30 minutes, initiated within 2 days of symptom onset
Indications
- Treatment of acute uncomplicated influenza in patients 6 months and older who have been symptomatic for no more than 48 hours
Mechanism of Action
- Inhibits influenza virus neuraminidase enzyme, preventing the release of viral particles from infected host cells and halting viral spread
Contraindications
- Known serious hypersensitivity to peramivir or any of its components (including anaphylaxis and severe cutaneous reactions)
Adverse Reactions
- Diarrhea
- Hypertension
- Insomnia
- Glucose fluctuations
- Serious skin reactions (e.g., Stevens-Johnson syndrome, toxic epidermal necrolysis)
- Neuropsychiatric events (hallucinations, delirium, abnormal behavior)
Drug Interactions
- Live attenuated influenza vaccines (LAIV): Antiviral drugs may inhibit replication of live vaccine virus and reduce vaccine efficacy; avoid administration of LAIV within 2 weeks before or 48 hours after peramivir administration unless clinically indicated
Curated Content: Needs Vetting Before Put to Clinical Use